objective(s): echis carinatus is one of the venomous snakes in iran. the venom of iranian echis carinatus is a rich source of protein with various factors affecting the plasma protein and blood coagulation factor. some of these proteins exhibit types of enzymatic activities. however, other items are proteins with no enzymatic activity.   materials and methods: in order to study the mechanism an...

Managing patients in the perioperative setting receiving novel oral anticoagulation agents for thromboprophylaxis or stroke prevention with atrial fibrillation is an important consideration for clinicians. The novel oral anticoagulation agents include direct Factor Xa inhibitors rivaroxaban and apixaban, and the direct thrombin inhibitor dabigatran. In elective surgery, discontinuing their use ...

BACKGROUND: This study aimed to assess compliance transfusion therapy recommendations in the clinical guidelines Extrauterine (ectopic) pregnancy with blood standards and achievements of evidence-based medicine transfusiology.
 THE MAIN PART: The assessed on ― 202120222023 (01.07.2021) approved by Russian Ministry Health (laws, governmental decrees, orders Health, instructions medicines, m...

http://dx.doi.org/10.1160/TH15-04-0324 Thromb Haemost 2015; 114: 1162–1163 Despite the proven efficacy of novel oral anticoagulants, bleeding still remains a serious complication (1–3). In case of lifethreatening conditions, immediate reversal of the anticoagulant effect is needed, regardless of the relatively short-half life of new direct anticoagulants. However, there is a lack of experience ...

The number of patients on antithrombotic treatment due to atrial fibrillation and venous thromboembolism is increasing fast due to an aging population. A growing proportion will be treated with novel oral anticoagulants, the first in clinical use was the direct oral thrombin inhibitor dabigatran (Pradaxa®). A small percentage of the patients on dabigatran will experience serious bleeding or be ...

Dear Editor, I read with interest the recent discussion on the ENGAGE-AF trial written by Kaba et al. The authors provide a comprehensive discussion of the novel oral anticoagulant (NOAC), Edoxaban. However, it is important to remind the readers that although NOACs are being promoted as first line for stroke prevention in atrial fibrillation, there is considerable risk of bleeding associated wi...

BACKGROUND AND PURPOSE Although intracerebral hemorrhage is one of the most serious complications during oral anticoagulant therapy, there are no guidelines on emergency treatment with respect to reversal of anticoagulation effect in these patients. METHODS We retrospectively compared laboratory data and clinical features in 17 cases of anticoagulant-related intracerebral hemorrhage treated w...

Dabigatran is an oral direct thrombin inhibitor (DTI) licensed for stroke prevention in atrial fibrillation and likely to be soon approved in Europe for treatment of venous thrombosis. Predictable pharmacokinetics and a reduced risk of intracranial haemorrhage do not negate the potential risk of haemorrhage. Unlike warfarin, there is no reversal agent and measurement of the anticoagulant effect...